tiprankstipranks
Celldex Therapeutics Inc (CLDX)
NASDAQ:CLDX
Holding CLDX?
Track your performance easily

Celldex (CLDX) Ownership - Who Owns Celldex?

1,073 Followers

Celldex (CLDX) Ownership Overview

0.36%37.56%<0.01%13.39%48.70%
<0.01% Other Institutional Investors
13.39% ETFs
48.70% Public Companies and
Individual Investors
The ownership structure of Celldex (CLDX) stock is a mix of institutional, retail, and individual investors. Approximately 50.94% of the company’s stock is owned by Institutional Investors, 0.36% is owned by Insiders, and 48.70% is owned by Public Companies and Individual Investors.
The ownership structure of Celldex (CLDX) stock is a mix of institutional, retail, and individual investors. Approximately 37.56% of the company’s stock is owned by Institutional Investors, 0.36% is owned by Insiders, and 13.39% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Jun 18, 2024
xxxxxxxxxxxxx
$608232
Jun 18, 2024
Elizabeth Crowley
Sr. Vp & Cpdo
xxxxxxxxxxxxx
$1045800
Jun 11, 2024
Elizabeth Crowley
Sr. Vp & Cpdo
xxxxxxxxxxxxx
$525750
Jun 11, 2024
Diane Young
Svp, Chief Medical Officer
xxxxxxxxxxxxx
$1586700

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Sep 30, 2024
xxxxxxxxxxxxx
$12724224
Sep 30, 2024
xxxxxxxxxxxxx
$79574702

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
4,547,257Institution6.85%120,638,728
3,643,437Institution5.49%96,660,384
3,352,884Institution5.05%88,952,013
3,071,673Institution4.63%81,491,485
2,550,423Institution3.84%67,662,722
2,341,121Institution3.53%62,109,940
1,829,744Institution2.76%48,543,108
1,482,620Institution2.23%39,333,909
1,323,404Institution1.99%35,109,908
1,185,264Institution1.79%31,445,054

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
4,547,257Institution6.85%120,638,728
3,352,884Institution5.05%88,952,013
3,071,673Institution4.63%81,491,485
1,482,620Institution2.23%39,333,909
1,323,404Institution1.99%35,109,908
1,185,264Institution1.79%31,445,054
1,132,864Institution1.71%30,054,882
1,051,077Institution1.58%27,885,073
764,252Institution1.15%20,275,606
761,430Institution1.15%20,200,738

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
2,089,178Institution3.15%54,443,979
1,683,048Institution2.54%46,452,125
1,721,510Institution2.59%45,671,660
999,772Institution1.51%26,054,058
481,612Institution0.73%12,777,166
321,401Institution0.48%8,870,668
294,365Institution0.44%7,671,152
197,265Institution0.30%5,140,726
112,364Institution0.17%2,981,017
76,115Institution0.11%2,019,331

FAQ

Who Owns Celldex Therapeutics Inc (CLDX)?
According to the latest TipRanks data, approximately <0.01% of the company's stock is held by institutional investors, 0.36% is held by insiders, and 48.70% is held by retail investors.
    What percentage of Celldex Therapeutics Inc (CLDX) stock is held by institutional investors?
    According to the latest TipRanks data, approximately <0.01% of Celldex Therapeutics Inc (CLDX) stock is held by institutional investors.
      What percentage of Celldex Therapeutics Inc (CLDX) stock is held by retail investors?
      According to the latest TipRanks data, approximately 48.70% of Celldex Therapeutics Inc (CLDX) stock is held by retail investors.
        Who owns the most shares of Celldex Therapeutics Inc (CLDX)?
        VANGUARD SPECIALIZED FUNDS owns the most shares of Celldex Therapeutics Inc (CLDX).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis